The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | April 2011 |
| End Date: | January 2013 |
Exploring the Role of Gut-associated TH17 in Microbial Translocation in HIV and HCV/HIV Co-infected Patients
The purpose of this research study is to explore what role immune cells within the gut (the
sigmoid colon) have locally and on the immune system of patients infected with HCV, HIV or
HCV/ HIV co-infection.
sigmoid colon) have locally and on the immune system of patients infected with HCV, HIV or
HCV/ HIV co-infection.
Objective 1: Characterization of the Gut Associated Lymphocytes (GALT) in HIV, HCV and
coinfected patients regarding the role of Th17 and cytokine profiles.
Hypothesis 1a: HIV and HCV/HIV coinfection is associated with changes in Th17 numbers and
functions in GALT.
Hypothesis 1b: HIV and HCV/HIV coinfection is associated with changes in cytokine profiles
in intestinal mucosa.
Objective 2: Identify the relationship between changes in Gut Associated Lymphocytes (GALT)
in HIV, HCV and coinfected patients and markers of microbial translocation.
Hypothesis 2a: Changes in GALT are associated with increase in microbial translocation in
HIV, HCV and coinfected patients.
coinfected patients regarding the role of Th17 and cytokine profiles.
Hypothesis 1a: HIV and HCV/HIV coinfection is associated with changes in Th17 numbers and
functions in GALT.
Hypothesis 1b: HIV and HCV/HIV coinfection is associated with changes in cytokine profiles
in intestinal mucosa.
Objective 2: Identify the relationship between changes in Gut Associated Lymphocytes (GALT)
in HIV, HCV and coinfected patients and markers of microbial translocation.
Hypothesis 2a: Changes in GALT are associated with increase in microbial translocation in
HIV, HCV and coinfected patients.
Inclusion Criteria:
- are at least age 18, but not older than 70 years old
- have HIV, HCV or both
- do not have HIV, HCV or both, and are having a screening colonoscopy or flexible
sigmoidoscopy for abdominal pain or colon cancer screening (control subject)
Exclusion Criteria:
- have a history of inflammatory bowel diseases (IBD) or suspected IBD
- have a history of autoimmune diseases including rheumatoid arthritis
- are taking systemic immunomodulators
- are pregnant
We found this trial at
1
site
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
Click here to add this to my saved trials
